Last updated: Nov 17, 2026, 12:00 AM

Audax Renovables S.A. Exchange (MC, EUR)

ADX.MC

1.11
-0.01 (-1.07%)
UtilitiesUtilities - Renewable
Invest Today
Invest Today
1 year return (CAGR)
-13.78%
3 year return (CAGR)
-3.82%
5 year return (CAGR)
-2.10%
10 year return (CAGR)
8.34%
Stock Analysis

Adobe 2026 Q3 – Is sentiment driving the price?

Read More
Marketcap
495.52M
Price/Sales
0.26
Ent value
1.38B
Price/Book
2.09
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
-1.24%
Trailing P/E
41.48
PEG
-
Forward P/E
10.13
EPS growth
-6.20%

Stock information

iO Charts Blog

What is a stock exchange? Operation, actors, examples

Read More

Stock chart

Loading...
Stock price data
Open1.11
Daily high1.12
Daily low1.08
Daily Volume399K
All-time high9.72
1y analyst estimate2.35
Beta1.11
EPS (TTM)0.03
Dividend per share0.00
Ex-div date1 Jul 2026
Next earnings date28 Feb 2026

Ready to capitalize on Audax Renovables S.A.'s growth potential?

Take the next step in your portfolio.

Invest Today

Downside potential

Loading...
Downside potential data
ADX.MCS&P500
Current price drop from All-time high-88.54%-2.82%
Highest price drop-97.22%-56.47%
Date of highest drop25 Apr 20139 Mar 2009
Avg drop from high-80.37%-10.64%
Avg time to new high71 days12 days
Max time to new high4937 days1805 days
News
Physician and biopharma executive brings more than 30 years of experience spanning pharmaceutical leadership, commercialization, drug pricing, reimbursement, and market accessWEST PALM BEACH, FL, Nov....
November 18, 2026
Novartis wins FDA approval for Cosentyx in adults with PMR, backed by phase III data showing sustained remission and steroid-sparing benefits.
November 18, 2026
Boost ROI with AI analytics, decentralized monitoring, EDC, stronger patient recruitment and retention, expanded lab capacity, and rigorous compliance.Dublin, Nov. 18, 2026 (GLOBE NEWSWIRE) -- "Allerg...
November 18, 2026
Pelabresib 144-week Phase III MANIFEST-2 data show sustained clinical effects in longest follow-up from a combination trial in first-line JAKi-naïve myelofibrosisKISQALI® six-year NATALEE analysis dee...
November 18, 2026
Gas markets are in flux, LNG cargoes are harder to secure, and Asia is quietly burning more coal again. That mix is unsettling for energy users, but it can reshape earnings power for companies tied to...
November 18, 2026
Boost ROI through next-gen delivery platforms that differentiate biologics, extend patent life, enable precision therapies and meet demand for non-invasive, connected care.Dublin, Nov. 17, 2026 (GLOBE...
November 17, 2026
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round.
November 17, 2026
On Tuesday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (NYSE:NVS) Cosentyx (secukinumab) 150 mg to treat adults with polymyalgia rheumatica (PMR) who respond inadequately to co...
November 17, 2026
Incyte secures EC approval for Povofortay, the first once-daily oral HS treatment in the EU, opening a new growth opportunity backed by strong clinical results.
November 17, 2026
Roche wins FDA approval for Wilserdly plus everolimus, offering an all-oral treatment option for advanced breast cancer and strengthening its oncology portfolio.
November 17, 2026